Novartis Gene Therapies News
By: Colorado BioScience Association Date: 03/26/2021
Work in Progress to Support Jobseekers and Identify New Candidates for Facility Novartis Gene Therapies, formerly AveXis, plans to wind down its Longmont facility in July. Novartis Gene Therapies has...
Learn MoreRobust Speaker Line-Up and Pitch Event Winner at CBSA-Amgen Healthcare Innovation
By: Colorado BioScience Association Date: 03/23/2021
The CBSA-Amgen Healthcare Innovation Event took place this week filled with engaging speakers and a robust audience. Thank you to our sponsors Amgen, Amgen Ventures and CBSA sustaining spons...
Learn MoreWeekly Policy Update: CBSA Testifies on Local Impact of Drug Pricing Bill
By: Colorado BioScience Association Date: 03/19/2021
This week CBSA testified in opposition to Senate Bill 175 in the Senate Health & Human Services Committee. The bill would create a prescription drug review board in Colorado that’s charged with re...
Learn MoreWeekly Policy Update: CBSA Engages on Key Legislation
By: Colorado BioScience Association Date: 03/12/2021
CBSA took new positions on several bills in the 2021 legislative session. Here is a recap of what happened this week. New Funding for Advanced Industries Grant Program: On Tuesday, the legislature pas...
Learn MoreColorado Vaccine Distribution Update
By: Colorado BioScience Association Date: 03/12/2021
The Colorado Department of Public Health & Environment (CDPHE) confirmed to CBSA that members of our life sciences workforce involved in the research, development, manufacturing and distribution o...
Learn MorePolicy + Advocacy: Legislature Passes New Funding for Advanced Industries Accelerator Grant Program
By: Colorado BioScience Association Date: 03/09/2021
On Tuesday, the Colorado General Assembly passed Senate Bill 42, which includes a one-time, $10 million infusion for the Advanced Industries Accelerator Grant Program. Governor Polis is expected to si...
Learn MoreWeekly Policy Update: CBSA Shares Survey Insights
By: Colorado BioScience Association Date: 03/05/2021
The CBSA Policy + Advocacy team works to engage state and federal policymakers on issues that are critical to our members and Colorado’s life sciences ecosystem. Last month, CBSA conducted a survey to...
Learn MoreThe Colorado Molecular Correlates Laboratory Puts Quality First
By: Colorado BioScience Association Date: 02/26/2021
The Colorado Molecular Correlates Laboratory is dedicated to the development and implementation of predictive, prognostic and diagnostic molecular biomarker testing that will permit selection of cance...
Learn MoreWeekly Policy Update: CBSA Takes Positions on New State Legislation
By: Colorado BioScience Association Date: 02/26/2021
The Colorado state legislature returned on February 16th to continue the 2021 session, and there have already been almost 300 bills introduced so far. CBSA’s Policy + Advocacy team has been hard at wo...
Learn MoreCBSA Joins Patient Community to Raise Awareness about Rare Diseases
By: Colorado BioScience Association Date: 02/25/2021
This week, CBSA joined the Colorado Rare Action Network for Colorado Rare Disease Day. The virtual event was an opportunity to educate state legislators and the public about the challenges rare diseas...
Learn More